The HSPG2 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of NCI-H1975 human lung adenocarcinoma epithelial cells, collectively carrying disrupted HSPG2 alleles. This heterogeneous pool provides a robust loss-of-function model to interrogate perlecan biology across varied knockout events, avoiding clonal biases inherent in single-cell-derived lines. It is suitable for functional studies requiring a representative knockout population.
The NCI-H1975 parental cell line was derived from a female patient with non-small cell lung cancer (NSCLC). It harbors an activating EGFR L858R point mutation and a secondary T790M gatekeeper mutation, while retaining wild-type TP53. These cells serve as a widely used model for investigating EGFR-targeted therapy resistance and signaling interactions in lung adenocarcinoma, particularly in the context of tumor microenvironment influences.
HSPG2 encodes perlecan, a large basement membrane heparan sulfate proteoglycan that functions as a scaffold for growth factor presentation. It binds FGF2, VEGFA, and PDGF-BB, facilitating their interaction with receptors such as FGFR1 and VEGFR2 to propagate downstream AKT and ERK signaling cascades. Perlecan also interacts with matrix ligands like laminin, collagen IV, nidogen, and integrin alpha2beta1, mediating cell adhesion and tissue integrity. Transcription is regulated by TGF-beta1, EGR1, NF-kB, and SP1, and its downstream effects extend to ITGB1-mediated adhesion and SMAD2/3, beta-catenin signaling, collectively influencing angiogenesis and proliferation.
In the NCI-H1975 EGFR-mutant background, HSPG2 knockout abolishes perlecan-dependent tethering of angiogenic and growth-promoting factors, likely attenuating both autocrine and paracrine signaling that drive tumor growth, migration, and angiogenesis. This disruption may uncouple EGFR from cross-activation of FGF and VEGF pathways, altering drug sensitivity and metastatic potential. The model thus enables dissection of how basement membrane proteoglycans modulate oncogenic signaling and therapeutic response in NSCLC.
These polyclonal knockout cells are suitable for diverse applications, including studying perlecan??s role in ECM-growth factor interactions, cancer cell adhesion, migration, and drug resistance. Representative assays include Western blotting, RT-qPCR, immunofluorescence, colony formation, transwell migration, VEGF ELISA, tube formation, and drug sensitivity testing. The heterogeneous knockout population provides a robust platform for functional genomics. For further information, contact Ascent Research.
